
LEO Pharma Showcases 12-Month Real-World Data on Tralokinumab at AAD 2026
LEO Pharma Showcases New Real-World Data on Tralokinumab at AAD 2026, Highlighting Benefits Across Diverse Atopic Dermatitis Populations LEO Pharma has presented new post-hoc analyses from its ongoing TRACE study, offering important real-world insights into the effectiveness of tralokinumab in…












